MCI and Brain Photobiomodulation | Clinical Results with Vielight Neuro
We are recruiting for a new n=60 MCI clinical trial with St. Michael’s Hospital, Toronto.
Mild Cognitive Impairment (MCI) is a condition that often precedes more severe forms of dementia, such as Alzheimer’s disease (AD).
A recent clinical study by researchers from the University of Toronto investigated whether a non-invasive technique called transcranial photobiomodulation (tPBM), which uses near-infrared light to stimulate brain cells, could improve brain function in individuals with MCI. The study utilized the Vielight Neuro RX Gamma (medical version of the Vielight Neuro Gamma), a cutting-edge device designed to deliver transcranial and intranasal PBM therapy.
What is Transcranial Photobiomodulation (tPBM)?
tPBM is a non-invasive treatment that uses near-infrared light to penetrate the skull and stimulate brain cells. This light energy is thought to enhance mitochondrial function—the powerhouse of cells—which can improve energy production and overall Brain wellness. The Vielight Neuro RX Gamma is a specialized device that delivers this light therapy directly to the brain through the scalp and nasal cavity, making it a convenient tool for home-based treatment.
The Study Design
The study involved 14 participants with MCI, who were randomly assigned to either an active tPBM group or a sham (placebo) group. Over six weeks, participants used the Vielight Neuro RX Gamma daily at home. The active group received real near-infrared light therapy, while the sham group received a placebo treatment with no therapeutic effect. Before and after the six-week period, participants underwent a series of tests to measure changes in brain function, including:
- Cognitive tests: Trail Making Test (TMT) and Mini-Mental State Examination (MMSE) to assess executive function and general cognitive abilities.
- Brain imaging: Structural MRI, resting-state functional MRI (rsfMRI), and Proton Magnetic Resonance Spectroscopy (H-MRS) to evaluate brain structure, connectivity, and metabolic changes.
- Blood tests: Analysis of biomarkers related to Alzheimer’s disease and mitochondrial function.
Key Findings
The results showed significant improvements in the active tPBM group compared to the sham group:
- Cognitive Function: Participants in the active group performed better on the Trail Making Test (TMT-B), which measures executive function, and showed a trend toward improvement on the MMSE, a general cognitive test.
- Brain wellness:
- H-MRS scans revealed a decline in the N-acetyl aspartate to total creatine ratio (NAA/Cr), a marker of neuronal health, suggesting improved brain metabolism.
- Structural MRI showed an increase in the volume of the right thalamus, a brain region involved in sensory and motor signaling.
- Resting-state fMRI demonstrated enhanced connectivity in key brain networks, including the default mode network (DMN) and limbic network, which are critical for memory and emotional processing.
- Blood Biomarkers:
- Levels of isoleucine, methionine, and sarcosine—markers linked to Alzheimer’s and amyloid plaque formation—decreased significantly.
- Levels of butyrate and L-carnitine—markers associated with improved mitochondrial function—increased, indicating better cellular energy production.
- Plasma Tau: While not statistically significant, there was a notable reduction in plasma tau levels in the active group. Tau is a protein linked to Alzheimer’s progression, and its reduction is a promising sign.
What Does This Mean?
The findings suggest that tPBM, delivered via the Vielight Neuro RX Gamma, may improve executive function, brain connectivity, and mitochondrial health while reducing markers associated with Alzheimer’s disease. These results are particularly exciting because they highlight the potential of a non-invasive, home-based therapy to slow or even reverse cognitive decline in individuals with MCI.
Limitations and Future Directions
While the results are promising, this was a small pilot study with only 14 participants. Larger studies are needed to confirm these findings and explore the long-term effects of tPBM. Additionally, future research could investigate whether tPBM can delay or prevent the progression from MCI to Alzheimer’s dementia.
Conclusion
This study offers hope for individuals with MCI and their families, suggesting that near-infrared light therapy, such as that delivered by the Vielight Neuro RX Gamma, could be a safe and effective way to improve brain function and potentially slow the progression of cognitive decline. As research continues, tPBM may become a valuable tool in the fight against Alzheimer’s disease and other forms of dementia.
This study represents an exciting step forward in the field of non-invasive brain therapies, and the Vielight Neuro RX Gamma stands out as a promising device for delivering these benefits.
